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Cell cycle regulationAlthough widely explored, the pathogenesis of Alzheimer’s disease (AD) has yet to be cleared. Over
the past twenty years the so call amyloid cascade hypothesis represented the main research para-
digm in AD pathogenesis. In spite of its large consensus, the proposed role of b-amyloid (Ab) remain
to be elucidated. Many evidences are starting to cast doubt on Ab as the primary causative factor in
AD. For instance, Ab is deposited in the brain following many different kinds of injury. Also, concen-
tration of Ab needed to induce toxicity in vitro are never reached in vivo. In this review we propose
an amyloid-independent interpretation of several AD pathogenic features, such as synaptic plastic-
ity, endo-lysosomal trafﬁcking, cell cycle regulation and neuronal survival.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction increase the cholinergic tone in AD brain was adopted. Later on,Alzheimer’s disease (AD) is the most common form of dementia,
with an estimated 24 to 35 million people affected worldwide [1].
Although it has been widely explored, the pathogenesis of AD has
yet to be cleared. According to the view that interprets many neu-
ropsychiatric disorders as neurotransmitter dysfunctions, during
the seventies and early eighties AD was looked at as a cholinergic
deﬁcit involving the cholinergic projection from the basal forebrain
neuronal population (the nucleus basalis magnocellularis of Meyn-
ert) to the cortex and hippocampus [2], similarly to Parkinson dis-
ease (PD) which was shown to be due to the degeneration of the
nigrostriatal dopaminergic ﬁbers. Since the cholinergic hypothesis
of AD was developed, once again similarly to PD, a pharmacological
approach based on inhibitors of cholinesterases addressed toover the past twenty years, when a more complex way to look at
the neurodegenerative diseases caught on, the so call amyloid cas-
cade hypothesis [3] became the main research paradigm in AD
pathogenesis.
Amyloid b protein (Ab), the major constituent of the senile pla-
ques (SP) [4] is, together with neuroﬁbrillary tangles (NFT), the
hallmark for the neuropathological conﬁrmation of AD [5]. Ab is
a peptide that has between 39 and 42 amino acid chains; the 42
amino acids form aggregates more avidly and is thought to be
implicated in the pathogenesis of the disease and is the basis of
the amyloid hypothesis. Abs are products of the proteolytic cleav-
age of amyloid precursor protein (APP), a ubiquitous, glycosylated,
sulfated, and phosphorylated integral membrane protein [6]. The
amyloid hypothesis infers the presence of two distinct pathways
for APP hydrolysis: the ‘‘amyloidogenic’’ and the ‘‘non-amyloido-
genic’’ pathway. The ﬁrst pathway is initiated by the b-secretase
enzyme, an identiﬁed aspartyl protease (BACE 1 and 2) which
cleaves the extracellular region of APP [7–9]. Subsequently,
c-secretase, a multiprotein complex containing at least presenilin
1, presenilin 2 and nicastrin, hydrolyses APP in the middle of its
transmembrane domain [10–12]. The large, soluble APP ectodo-
main, APPs-b and Abs are released extracellularly. The alternative
pathway of APP hydrolysis is referred to as ‘‘non-amyloidogenic’’
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domain precluding the formation of Ab. In this case, the c-secre-
tase activity produces P3, a 24 or 26 amino acid containing peptide,
and APPs-a, a large soluble protein released extracellularly [13,14].
a-Secretase cleavage is the major pathway of APP processing,
which is mediated by a disintegrin and metalloproteinase ADAM10
or ADAM17 [15].
The pathogenic role of Ab in AD is sustained by several lines of
evidence. Themain support comes from the observation that muta-
tions in APP or in presenilins genes, leading to overexpression of Ab,
are associated with familial forms of AD (FAD). Furthermore, trans-
genicmice harboring the humanmutations bear strong similarity to
AD and ﬁnally, Ab is shown to be toxic to neurons in culture and
when administered intracerebrally to experimental animals. In
accordance with this hypothesis, Ab emerges as a molecule with a
variety of cytotoxic effects. For instance, Ab is able to affect the
mitocondrial redox activity [16] to increase the production of free
radicals [17], to damage the intracellular calcium homeostasis
[18], to induce the formation of selective calcium channels [19], to
induce the release of cytokines [20], to increase the effects of other
toxic agents such as excitatory aminoacids [21] or lack of glucose
[22], and to increase the enzymatic activity of phospholipases A2,
C and D [23]. More interestingly, it was also shown that Ab is able
to negatively regulate the synthesis and release of ACh from the ba-
sal forebrain cholinergic system [24,25].
However, recent evidence suggests alternative mechanisms for
AD pathogenesis and outline how Ab, which is only one of the
many products of the APP breakdown, may be regarded as a reac-
tive entity to potentially pathogenic stimuli. Even the genes in-
volved in Ab metabolism, whose mutations may cause FAD, could
be involved in additional mechanisms besides the ones associated
with Ab metabolism.
The aim of the present work is to reevaluate the role of Ab in AD
pathogenesis and to suggest possible alternative ways to look at
the classic amyloid hypothesis proposed almost twenty years ago.
2. Is Ab the primary culprit in AD?
In spite of the large consensus, theproposed role ofAb inADpath-
ogenesis remains to be elucidated. Although several genetic evi-
dence suggest an important pathogenic role for Ab, a major remark
that casts doubt on the amyloid hypothesis is the observation that
just a small number of AD cases, comprised between 1% and 5%,
are linked to a genetic mutation. The cause of most late-onset AD
cases (LOAD) still remains unclear, as the likelihood of developing
LOAD is linked to the interaction between environmental factors
and a number of susceptibility genes such as the well known apoli-
poprotein E (APOE) gene [26,27]. Currently,more than30 FADmuta-
tions have been mapped on the APP gene. Interestingly, APP
mutationsof the London type,whichcause relatively small increases
in Ab, induce AD at earlier ages than the Swedish mutation, which
causes much higher increases in Ab [28], suggesting that other
mechanisms may be involved.
Another strong point against the arguments supporting the
cause of senile plaques as main players in the etiology of AD is that,
although long considered one of the hallmarks of AD, they are not
speciﬁc to AD. The frequency of SP rises with the age in healthy
controls [29] and the number of plaques in cognitively healthy
people is comparable to the one observed in affected people [30].
Even in the AD population, there is only a weak correlation be-
tween plaque load and severity of dementia.
Perhaps more importantly, there is strong evidence of deposi-
tion of Ab as a reaction to different kinds of brain injury, such as
head trauma and cerebral ischemia. In general, data has demon-
strated that stress, speciﬁcally of a type that can induce metabolicstress by lowering the energy supply, induces a Ca2+ overload and a
consequent up-regulation of APP and its mRNA [31–37] suggesting
that the overproduction of Ab has to be regarded as a non-speciﬁc
phenomenon.
A further remark that may question the validity of the amyloid
hypothesis is the description of several pathological conditions
including sporadic cerebral amyloid angiopathy [38] and heredi-
tary cerebral hemorrhage with amyloidosis of Dutch type [39],
which show levels of amyloid pathology similar to AD without
any overt dementia, suggesting once again that amyloid alone is
insufﬁcient to cause neuronal loss and cognitive symptoms ob-
served in AD.
Finally, further evidence that suggests an alternative way to
consider the amyloid hypothesis comes from several clinical trials
which used either active or passive immunization in order to stim-
ulate the Ab clearance from the brain of AD patients. Although
immunization with Ab-42 resulted in enhanced clearance of amy-
loid plaques, this did not prevent progressive neurodegeneration
and cognitive deterioration [40]. Moreover, despite the evidence
of a good safety proﬁle and good signals of pharmacodynamic
activity, even anti-Ab monoclonal antibodies (bapineuzumab and
solanezumab) did not demonstrate signiﬁcant clinical effects in tri-
als conducted on mild to moderate AD [41,42]. Even more signiﬁ-
cant is a recent study that compares the Fluorodeoxyglucose
(FDG)-PET and Pittsburgh compound B (PIB)-PET patterns in three
groups of AD variants (logopenic variant of Primary Progressive
Aphasia (PPA), Posterior Cortical Atrophy (PCA) and early onset
frontal variant) and suggests an only partial role of ﬁbrillar Ab
deposition in determining clinical phenotypes. Although FDG-PET
revealed a focal pattern of hypometabolism corresponding to these
speciﬁc clinical aspects, PIB-PET detected a diffuse hypocaptation
of the tracer without differences between the three groups. There-
fore, it is not the distribution of cerebral amyloid deposition, but
rather the position of the areas of focal hypometabolism to be re-
lated with distinct clinical features of the AD variants. Thus, the
amyloid deposition only partially explains the overall clinic-ana-
tomical heterogeneity of AD [43].
The role of Ab as responsible for the cholinergic deﬁcit in AD can
also be questioned. For instance, in the brain of 8 months old trans-
genic Tg2576 mice, when there is no accumulation of Ab yet, re-
duced binding levels of cortical and hippocampal M1 mAChR
were observed [44]. Recent data shows as well that the reduced
hippocampal release of ACh was due to a signiﬁcant increase in
the rate of high afﬁnity choline uptake, suggesting a possible com-
pensatory mechanism in response to an impairment of the cholin-
ergic synapses [45,46].
In conclusion, it is critical that NFT burden correlates better
than SP with cognitive decline, but the best correspondence is
shown by cortical synaptic loss [29,47–50]. In fact, failure in synap-
tic transmission and further disturbance of the neuronal circuits is
a signiﬁcant pathogenic aspect of AD. Furthermore, it was demon-
strated that extracellular deposition of ﬁbrillar Ab is not required
for the development of synaptic function impairment. In particular,
it was shown that overexpression of mutant human APP in the
neurons of transgenic mice decreases the density of presynaptic
terminals and neurons before these mice develop amyloid plaques
[51].
3. Synaptic plasticity in AD
3.1. The role of presenilins
There is a growing body of evidence to show that presenilins
(PSs) could be involved in synaptic plasticity. To support this role
of PS1, there is data demonstrating that PSs are localized in
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late in presynaptic terminals of PScDKO mice, conditional knock-
out mice lacking both presenilins in the postnatal forebrain [53].
In fact, presenilins appear to be involved in neurotransmitters re-
lease and synaptic scaling independently from their c-secretase
function [54,55]. Loss of PS function in the presynaptic terminal
speciﬁcally disrupts ryanodine receptor-mediated Ca2+ release
from the ER store, resulting in reduced increases of the Ca2+ re-
leased during the action potentials in the presynaptic terminal.
This effect lowers the probability of neurotransmitter release,
and the decreased glutamate release causes long-term potentiation
(LTP) impairment in PS-deﬁcient presynaptic terminals [28]. In
fact, it was demonstrated that N-methyl-D-aspartate receptor
(NMDA)-mediated responses were impaired (Fig. 1A). In particular,
post-synaptic levels of subunits of the NMDA receptor were signif-
icantly lower in the absence of PS1 [56]. Loss of PS reduces levels of
cAMP response element-binding protein (CREB)-binding protein
(CBP) and transcription of CREB/CBP target genes, even though
CREB-mediated transcription is regulated indirectly by PS
(Fig. 1B) [57]. It is also worth noting that PScDKO mice developed
neuronal, synaptic and dendritic degeneration in an age-dependent
fashion with simultaneous astroglyosis, tau phosphorylation and
synaptic impairment which precede progressive neurodegenera-
tion, suggesting that PS1 missfunction ﬁrst induces synaptic loss,
which in turn boosts progressive neurodegeneration [56,58,59]. A
study conducted on Shaffer collateral circuits provides highly
intriguing data and allows for further understanding of the roles
of PSs in synaptic function. In this study, PS1 was alternativelyFig. 1. Picture of PS and mTOR pathways implication in synaptic plasticity Lack of PS lead
decrease of glutamate release and a Long-Term Potentiation (LTP) impairment. On the o
rector (AChR) activation, responsible for reduced NMDA currents. Mammalian Target o
(NFTs) formation through the detachment of tau from axonal microtubules and its captu
synaptic transmission. PS is involved in Notch intracellular domain (NICD) release from
results in Notch pathway inactivation, inducing synaptic dysfunction and alterations o
trascription (details in the text).inactivated in CA1 and CA3 neurons, providing, alternatively, pre-
and post- synaptic inactivation [52]. Interestingly, when the pre-
synaptic PS1 was inactivated the h burst-induced LTP was dimin-
ished, whereas this did not occur when the post synaptic PS1
was inactivated. Moreover, the defects in the synaptic facilitation
were found to be dependent on both the frequency of stimulation
and external concentrations of Ca2+.
Interestingly, carbachol, a muscarinic agonist, or the cholines-
terase inhibitor PT were tested too on hippocampal slices from
PS1KI mice, resulting in impaired LTP at CA1 synapses. Further-
more, NMDA current amplitude was signiﬁcantly lower in CA1
neurons or basal forebrain cholinergic neurons expressing PS1
mutation alone or in combination with an APP mutation. This data
strongly suggests that the cause of this synaptic misfunctioning is
not a major structural abnormality but rather a disruption of the
biological activity of PS1 as a Ca2+ leak channel [60]. The loss-of-
function mechanism is supported by the ﬁnding that cells lacking
PS1 exhibit impaired Ca2+ responses to glutamate [61]. Excessive
Ca2+ release in response to muscarinic receptor activation could ex-
plain the impairment caused by carbachol and PT in neurons
expressing mutant PS1. Excessive elevation of intracellular Ca2+
could also be responsible for reduced NMDA currents. Accordingly,
Ca2+ chelator restored NMDA currents in CA1 neurons of PS1KI
mice as well as in 3xTgAD mice. This latter ﬁnding, considering
that 3xTgAD mice show Ab oligomers and hyper-phosphorylated
tau, suggests that the misfunctioning is not related to Ab accumu-
lation or hyper-phosphorylated tau [60]. Laursen et al. [62] in-
duced partial basal forebrain cholinergic degeneration in Tg2576s to a reduction of ryanodine receptor (RyR)-mediated Ca2+ release from ER causing a
ther hand, PS1 mutations cause an excessive Ca2+ release in response to muscarinic
f Rapamycin (mTOR) signaling seems to be implicated in NeuroFibrillary Tangles
re into somatodenditic compartments, leading to the impairment of glutamatergic
a truncated Notch construct and in intracellular cAMP production. PS deﬁciency
f cAMP response element binding (CREB)/CREB binding protein (CBP) target genes
644 P. Sorrentino et al. / FEBS Letters 588 (2014) 641–652mice (overexpressing a mutant form of APP and accumulating Ab).
Interestingly, at 9 months, sham lesioned mice showed no deterio-
ration of cognitive learning (despite Ab accumulation), whereas the
lesioned mice showed impaired working memory and mid to long-
term memory. This data further stresses the idea that Ab accumu-
lation alone cannot justify the phenotype, and it is possible rather
that some misfunction of the Schaffer collateral in response to ba-
sal forebrain cholinergic stimulation (partly justiﬁed by the afore-
mentioned mechanisms involving APP and PS1 functioning) could
justify the phenotype and, at a later stage, the degeneration of
these neurons.
Another interesting observation refers to PS1 effect on the
Notch pathway. In mammalian cells, PS1 deﬁciency reduces the
proteolytic release of Notch intracellular domain (NICD) from a
truncated Notch construct, thus identifying the speciﬁc biochemi-
cal step of the Notch signaling pathway that is affected by PS1
(Fig. 1B). Moreover, several c-secretase inhibitors block this same
step in Notch processing [63]. It is reported that the impaired
Notch signaling is involved in synaptic plasticity and late-onset
cognitive decline. In fact, in the hippocampus of adult mice, re-
duced Notch levels (by transgenic antisense construct expression)
lead to impaired long-term potentiation (LTP) and enhanced long-
term depression (LTD) [64]. Moreover, Notch pathway activation
causes a decrease in neurite branching with consequent reduction
in the release of neurotransmitters. Furthermore, in dysfunctional
neurons with Notch hyper-activation, neuronal morphology was
reverted using Notch-inhibiting agents [65].
3.2. The role of APP
Although not as much evidence has been produced as for PS1,
data is starting to show a role for APP in synaptic functioning. More
precisely, some synaptic dysfunction could be due to loss-of-func-
tion of APP because of a deﬁcit in the production of sAPPa. Infact,
sAPPa shifts the frequency dependence for the induction of LTP
and LTD so that LTP is enhanced and LTD is decreased [66]. These
effects could be mediated both by local actions [67] or transcripted
mediated actions [66]. Furthermore, studies with cultured hippo-
campal neurons have showed that sAPPa has a strong neuropro-
tective action [67,68]. This ﬁndings show that at least part of the
dysfunction ﬁrst and neurodegeneration then could be explained
by mechanisms involving APP other than Ab formation and/or
accumulation.
3.3. The role of mTOR
In the latest literature, great attention has been cast on the role
played by mammalian Target of Rapamycin (mTOR) disregulation
in AD. The PI3-K/Akt/mTOR pathway and its activation by IGF-1R
and IR is demonstrably disturbed in the brains of individuals with
AD compared with the controls, and many of these measures cor-
relate with disease severity [69–72]. In particular, the levels of
mTOR targets are also upregulated in the AD brain (Fig. 1C) [73].
Ma et al. [74] treated cells from hippocampal slices of Tg2576mice,
which harbor the human APP Swedish mutation (the mice develop
AD-like amyloidosis and memory deﬁcits), with FSK (LTP inducer)
and with DHPG (LTD inducer) showing a muchmilder upregulation
of fP-p70S6K, a mTOR activity marker, as compared with wild type
mice (WT). Moreover, alteration in synaptic plasticity was studied
by performing high frequency stimulation (HFS) and paired pulse
facilitation (PPS) in order to assess effects on postsynaptic and pre-
synaptic plasticity, respectively. Strikingly, LTP was inhibited in
Tg2576 mice, as compared to WT, with HFS but not with PPS. Thus,
the data showed impairment in LTP that correlates well with im-
paired upregulation of mTOR signaling. Furthermore, upregulation
of the mTOR pathway seems to be able to rescue Ab relatedinhibition of LTP. Lastly, in hippocampal slices prepared from APP
knockout mice, Ab treatment couldn’t signiﬁcantly alter the levels
of phosphorylated p70S6K, supporting a role for APP processing
and intraneuronal Ab in downregulation of mTOR signaling [74].
mTOR signaling is selectively increased in neurons that are
predicted to develop NFTs [71]. NFTs are intraneuronal inclusions
composed of hyperphosphorylated forms of the microtubule-
associated protein Tau. Whereas Tau normally contains 2–3 mol
of phosphates per mole, Tau phosphorylation levels in AD brains
undergo a three to four fold increase. Upon hyperphosphoryla-
tion, Tau dissociates from the microtubules and subsequently
sequesters normal Tau and other microtubule-associated pro-
teins, which inhibits assembly and depolymerizes microtubules
[75]. Tau is phosphorylated at numerous serine and threonine
residues. Several of these residues have been shown to be depen-
dent on Protein phosphatase 2 (PP2A) activity [76–78]. The mTOR
pathway regulates PP2A activity [79]. It is worth noting that
when using metformin as an mTOR inhibitor, activation of
PP2A was observed as well as tau dephosphorilation in vitro
and in vivo in a PP2A-dependent manner [78]. Glycogen synthase
kinase-3 (GSK-3) has been shown to phosphorylate Tau at most
sites which were hyperphosphorylated in AD. GSK-3 is antago-
nized by PP2A, both are tightly regulated in neurons. Within this
context, it is likely that when mTOR is overexpressed, the earliest
events are the detachment of tau from axonal microtubules and
its capturing into somatodendritic compartments (Fig. 1C). In-
creased levels of somatodendritic tau have been shown to mod-
ulate and impair aspects of normal glutamatergic synaptic
transmission and LTP/LTD [80,81].
In conclusion, several reports demonstrate that inhibiting
mTOR by using rapamycin alleviates both Ab and Tau misfolding
and show its pathogenic role in AD animal models and its impact
on cognitive function restoration [82–84].4. Neuronal proliferation and survival in AD
4.1. The role of presenilins
In addition to their proteolytic roles culminating in Ab produc-
tion, PSs have been shown to interact with various proteins in-
volved in the regulation of c-secretase activity, cell proliferation,
survival, development and signaling (Fig. 2). For example, PS1 pro-
motes the cleavage of other transmembrane proteins such as
Notch1, E-cadherin, APP, low density lipoprotein receptor-related
protein, CD44 and the ErbB4 receptor [85].
As stated above, PSs are implicated in Notch signaling which
also regulates the cell cycle. In fact, treatment of Neuronal Stem
Cells (NSCs) derived from human embryonic stem cells, with the
Notch inhibitor (DAPT), decreases cyclin-dependent kinase 4
(CDK4) and S-phase kinase-associated protein 2 (SKP2) levels,
and increases the levels of cell cycle inhibitors such as cyclin-
dependent kinase inhibitor 1B (p27KIP1). This extends the G1–
S transition, and if Notch signaling levels remain low, the cell ex-
its the cycle and differentiates into a neuron [86–88]. A further
involvement of PS1 in cell cycle progression was demonstrated
by Nizzari et al. [85] showing that both APP and PS1 interact
with GRB2 (growth factor receptor-bound protein 2) adaptor
protein in vesicular structures at the centrosome of the cell.
The centrosome is a crucial region for microtubule nucleation,
cell cycle progression, migration, cytokinesis, and cellularization
[89]. The ﬁnal target for these interactions is ERK1,2, which is
activated in mitotic centrosomes in a PS1- and APP-dependent
manner. This data suggests that both APP and PS1 can be part
of a common signaling pathway that regulates ERK1,2 and the
cell cycle. Currently, it is tempting to speculate that ERK1,2
Fig. 2. A schematic representation of neuronal cell cycle and microtubule stability regulation mediated by presenilin 1 (PS1) and APP. The continuous arrows indicate the
mechanisms activated by PS1; the products of APP cleavage, sAPPa, sAPPb and AICD, regulate the pathways illustrated by the dotted arrows. ERK 1,2 activation is mediated by
both PS1 and APP (details in the text).
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Tau phosphorylation and neuroﬁbrillary tangles formation
(NFT), considering that centrosomes are essential for microtubule
stability and assembly [85]. The formation of Ab peptides has
been previously described in different compartments, from early
endosomes to Golgi, ER, and also close to the cell surface, and
only recently a close interaction APP-PS1 was described near
the cell membrane rather than in the Golgi-ER [90]. Nonetheless,
to our knowledge the centrosomal area was never analyzed as a
possible site of interaction for these proteins or for the formation
of intracellular amyloid [85].
In the context of microtubule stability regulation, Notch signal-
ing still seems to be involved. It can modulate neuronal migration
and early differentiation in primary cortical neurons. Treatment
with the Notch ligand JAG1 downregulated spastin, a protein in-
volved in severing microtubules, and this resulted in increased
microtubule stability. Immunostaining for acetylated a-tubulin re-
vealed notable increases in microtuble branching and neurite
thickness in these cortical neurons. This effect on microtubule sta-
bility could be blocked by c-secretase inhibition, indicating that it
is dependent on NICD [91].
4.2. The role of APP
Several studies demonstrate the neuroprotective and neuropro-
liferative effects of sAPPa on adult neurons [92,93]. Indeed, mice
lacking APP (APP-KO) show a smaller brain size and reduced body
growth [94] and studies show that expression of sAPPa alone can
rescue the growth and brain weight deﬁcits [95]. Thus, there is
now overwhelming evidence that sAPPa exerts a positive,
growth-promoting effect on both neuronal precursor stem cells
as well as adult neurons. The novel conclusion of this study is that
sAPPa is a general proliferation factor for stem cells of multiple lin-
eages since APP is ubiquitously expressed and sAPPa stimulates
the proliferation of diverse stem cell populations. A recent study
[96] shows that both sAPPa and sAPPb, generated in a roughly
9:1 ratio, stimulated axon growth via ERK activation and thatamino-terminally secreted products of APP, and sAPPb in particu-
lar, caused a rapid and robust differentiation of pluripotent human
embryonic stem cells toward a neural fate (Fig. 2). Together, these
studies suggest that APP processing, but not Ab formation, has a
stimulating effect on both neural stem cell proliferation and differ-
entiation [15].
The cleavage of APP also results in the release of cytosol-soluble
peptides containing carboxy terminal fragments (CTFs). Several of
these peptides, among which the intracellular APP domain (AICD),
can translocate to the nucleus and regulate gene expression [97]
whereas others remain in the cytoplasm and regulate the stability
of transcription factors [98]. Moreover, AICD in murine models
simulates many characteristics of AD [99]. In fact, another study
which supports the ‘‘non-amyloidogenic’’ hypothesis highlights
that the cleavage of APP by presenilins, which generates Ab, also
releases APP intracellular domain (AICD) from the membrane
[100]. AICD expressing transgenic mice recapitulate many AD fea-
tures such as activation of GSK3b, phosphorylation and aggrega-
tion of Tau, deﬁcits in working memory and abnormal neural
activity and silent seizures [99,101,102]. Interestingly, these
pathologies were observed without appreciable changes in APP
metabolism or Ab generation. Since AICD levels are elevated in hu-
man AD brains [101], these ﬁndings raise the possibility that AICD,
in addition to Ab, signiﬁcantly contributes to AD pathogenesis.
Furthermore, a study conducted by Ghosal et al. [100] demon-
strates that AICD transgenic mice also exhibit impaired adult neu-
rogenesis due to reduced neuronal proliferation and survival. This
impairment is observed even in the absence of endogenous APP
demonstrating that AICD alone is capable of inducing the deleteri-
ous effects. Importantly, the defects in adult neurogenesis are pre-
vented by long-term treatment with the non-steroidal anti-
inﬂammatory agents ibuprofen or naproxen, suggesting that neur-
oinﬂammation is critically involved in impaired adult neurogenesis
in AICD transgenic mice. The same study shows that AICD impairs
adult hippocampal neurogenesis in an age-dependent manner.
Adult neurogenesis was normal in 6-week-old AICD transgenic
mice but was reduced at 3 months of age and the impairment
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due to decreased cell proliferation and survival and not to altered
differentiation (Fig. 2). The defective neurogenesis is mediated by
non-cell-autonomous mechanisms involving proinﬂammatory
changes. The important ﬁndings of this study are that impaired
adult neurogenesis in AD is due to neuroinﬂammation and that
the overexpression of AICD impairs adult neurogenesis in an Ab
independent fashion [100].
5. Endo-lysosomal trafﬁcking impairment: AD as a storage
disease
Another line of evidence that suggests an alternative way to
look at AD pathogenesis is the composition of the SPs. Inside the
plaques there is a very high incidence of swelling of axons and den-
drites [103]; areas of dystrophic swelling were later shown to be
ﬁlled with autophagic vacuoles [104]. The actual quantity of vacu-
oles accumulated in dystrophic neurites in AD is signiﬁcantly high-
er than in any other aging-related neurodegenerative disease
[104–106]. Furthermore, the pattern of impaired autophagy dis-
played in mouse models of AD indicates a speciﬁcally autophagy-
related disruption rather than a general failure of the whole axonal
transportation. Indeed, a very interesting comparison between the
burden of undigested proteins in AD and that seen in many pri-
mary lysosome storage disorders has been proposed [107].
From a genetic perspective, there is a growing body of evidence
suggesting that PS1 and APP are both involved in the regulation of
intracellular trafﬁcking. Speciﬁcally, mutations in PS1 and APP (as
well as APP duplication) disrupt cellular autophagy and endocyto-
sis in an Ab-independent manner. The lysosome system seems to
be the most involved, which is highly signiﬁcant considering that
neurons almost exclusively use lysosomes to achieve protein clear-
ance [108–110].
5.1. The role of presenilins
PS1 appears to be essential for lysosomal proteolysis by permit-
ting the lysosomal acidiﬁcation needed for the activation of prote-
ases [109]. It has been observed that neurons lacking PS1 did not
have vATPase delivered to lysosomes. PS1 facilitates the N-glyco-
sylation of the V01A subunit of vATPase in the ER before being
cleaved and integrated in the c-secretase complex. This is neces-
sary to achieve its correct delivery to lysosomes and for the correct
assembly of the protonic pump [109]. These mechanisms suggest
that PSs are involved in the regulation of the gene network associ-
ated with lysosomial biogenesis [111], affecting autophagy/lysoso-
mial proteolysis. In fact, in cells deﬁcient in PS, a multivesicular
endosomes (MVEs) expansion was found, along with an increased
Wnt responsiveness similar to the one obtained with chloroquine,
a lysosomal inhibitor [112]. Canonical Wnt signaling is essential for
embryonic development, stem cell and tissue homeostasis and
regeneration in the adult [113,114], while aberrant Wnt signaling
has been associated with human diseases such as cancer, bone dis-
orders and neurodegeneration [115,116]. Binding of Wnt ligand to
their receptors Frizzled (Fz) and LDL-receptor related protein 5/6
(LRP5/6) triggers the recruitment of Dishevelled (Dvl), Axin and
GSK3 to plasma membrane [117,118]. Wnt receptor complexes,
containing Axin and GSK3, are then internalized into the cell by
endocytosis and subsequently sequestered by incorporation into
the intraluminal vesicles (ILVs) of late endosomes that are pro-
duced by invagination and scission from the endosomal limiting
membrane [112,119]. Presenilin deﬁciency increases the stability
of multiple GSK3 substrates upon Wnt signaling (Fig. 3). One of
these substrates is the microtubule-associated protein Tau, that
plays a crucial role in the pathogenesis of AD [112].Therefore, the new connection between Wnt signaling and
increased stability of GSK3 phosphorylation protein targets in
PS-deﬁcient cells could explain why AD neurodegeneration is most
severe in the hippocampus, especially in its dentate gyrus and
cerebral pyramidal neurons [120], for it is in these particular cells
that physiological Wnt signaling in the adult brain is maximal
[112,121].
5.2. The role of APP
It has been recently shown that APP gene triplication is needed
to see the development of endosomal pathology in neurons. More
interestingly, it was also observed in ts65dn mice that it was pos-
sible to improve the NGF retrograde transport by making the mice
diploid. In the same model it was also shown that there was no sig-
niﬁcant age-related variation of either Ab-40 or Ab-42, showing
that a genetic variation of APP can induce endosomal pathology
and/or cellular death in an amyloid-independent manner. In a form
of AD caused by APP gene duplication and in Down syndrome,
where a chromosome 21 segment containing APP is trisomic, endo-
some dysfunction can be attributed to the extra copy of APP [122–
124] and has been linked to altered trophic signaling, cholinergic
neurodegeneration [123] and activation of apoptotic pathway
[125]. Recently, these effects of increased APP dosage were shown
to bemediated speciﬁcally by the b-cleaved C-terminal fragment of
APP [124], previously known to have neurotoxic properties rele-
vant to AD [28,126–129].
Additional recent data provides further evidence that genes
implicated in endocytosis, such as rab5, rab7 and rab4, are among
the ﬁrst to be upregulated in AD well before Ab accumulation and
are abnormally recruited to endosomes [130]. In recent years PI-
CALM, a gene associated with an increased risk of developing
late-onset AD, was investigated. The precise contribution of PI-
CALM is not fully understood, but could include a role in APP pro-
cessing through the endocytic pathway, synaptic fusion and the
formation of memory through the trafﬁcking of VAMO-2 [131,132].
6. APOE and other risk factors within the amyloid-independent
hypothesis
In humans, APOE is located on chromosome 19 and encodes 3
common alleles: APOEe2, APOEe3 and APOEe4 [133]. The presence
of APOEe4 represents the most important and largely documented
risk factor for LOAD [26], APOE e3 is associated with neutral risk
and APOEe2 is associated with decreased risk [134]. However, even
this observation can be explained within alternative interpreta-
tions of the available evidence. Several experimental pieces of evi-
dence suggest that Apoe levels rise after different types of insult to
the CNS and PNS [135]. Therefore, Apoe4 would be associated with
AD not because it actually helps the formation of plaques, but be-
cause it is less efﬁcient in preventing the death of the neurons than
other alleles. In the brain, apoE is implicated in cholesterol trans-
port, while a signiﬁcant body of work supports apoE involvement
in synaptogenesis [136], neurite outgrowth [137–142], and den-
dritic arborization [143,144], modulation of synaptic plasticity
[145–147], neurogenesis [148,149], and neuroinﬂammation
[150], often with isoform-speciﬁc efﬁcacy. ApoEe3 and ApoEe4 dif-
fer by only one amino acid; in particular, ApoEe3 has cysteine at
residue 112, while ApoEe4 has arginine at the same residue. These
amino acid changes have a profound effect on the structure of the
protein and are therefore thought to play a fundamental role in the
association of ApoE with AD risk [133]. Neuronal production of
ApoE appears to be driven by astrocytic signaling mechanisms
[151], particularly as a result of neural injury. It has been demon-
strated in post-mortem human samples that ApoE4 undergoes
A B
Fig. 3. Model of Wnt-GSK3 Complex internalization with (A) and without (B) PS1 activity, through Multivesicular Endosomes formation. (A) The binding of GSK3 to the Wnt
Complex (Wnt, Frizzled, LRP5/6, b-Catenin, Dvl, Axin and APC) sequesters GSK3-Wnt complex inside small vesicles, causing b-Catenin, inactivation through Multivesicular
Endosomes (MVE) formation and Lysosomal degradation. (B) Lack of PS1 leads to a non-glycosylated protonic pump with consequent impairment of lysosomal activity. In the
absence of lysosomal degradation, MVEs accumulate and GSK3 and other proteins of GSK3-Wnt complexes become stabilized (details in the text).
P. Sorrentino et al. / FEBS Letters 588 (2014) 641–652 647neuron-speciﬁc proteolysis [152]; this dramatic increase in intra-
cellular cleavage of ApoE4 compared with ApoE3 and apoE2 is
thought to be caused by apoEe4’s much greater tendency to exhibit
domain interaction because of its structure. Although neurons take
up ApoE secreted by astrocytes, as demonstrated in transgenic
mice, the proteolysis occurs in the neuronal secretory pathway.
In fact, ApoE4 cleaved by ApoE Cleaving Enzyme (AECE) and miss-
ing residues 272–299 (D272–299) is capable of translocating into
the cytosol to escape the secretory pathway [133].
In Neuro-2a cells, ApoE4 (D272–299) has been found to interact
with cytoskeletal proteins to form neuroﬁbrillary tangle-like
structures containing phosphorylated tau [152]. Mice expressing
high levels of ApoE4 (D272–299) in neurons display AD-like
neuroﬁbrillary tangles and die at 2–4 months. With lower levels
of expression, the mice display learning and memory deﬁcits at
6–7 months [153]. In addition to its deleterious effects on intracel-
lular transport, ApoE4 has been shown to have direct effects
on mitochondria. In Neuro-2a cultures, ApoE4 (D272–299)
signiﬁcantly reduces respiratory function of both complex III and
complex IV [154], while transgenic mice expressing human ApoE4
display impaired axonal transport, with mitochondria accumulat-
ing in bulb-like dilations [133,155].
Finally, ApoE could bind Ab and clear the extracellular peptide
by endocytosis and subsequent degradation [156]. AlthoughAPOEe4 allele represents the most important risk factor for LOAD,
many patients do not present APOEe4 allele, whereas individuals
carrying the APOEe4 allele may never develop AD, suggesting that
there might be other susceptibility genes and environmental fac-
tors involved in the appearance of the disease [27].
More recently, genome-wide association studies (GWAS) have
proposed new genes associated with LOAD. The CLU gene, encod-
ing clusterin (also known as apolipoprotein J) seems to be related
to Ab clearance by endocytosis [157,158]. Bin1 and PICALM, more
genes evidenced by GWA studies, are also involved in clathrin-
mediated endocytosis [159,160]. A very interesting gene is SORL1,
which encodes SorLA, a protein involved in endocytic trafﬁcking.
Sort1/mice show an early decrease in ChAT (choline acetyltran-
ferase), -immunoreactive neurons in the Basal forebrain (BF). These
ﬁndings match with the overall observed decrease in memory
functions, such as non-spatial and spatial memory in Sort1/
mice. It has been recently reported that in neurons lacking sortilin,
the production of sAPPa [161,162] and the catabolism of the
amyloid peptide by APOE are decreased [163]. In conclusion,
beside the classical mutations on APP, PS1 and PS2 responsible
for FAD, many new genes are coming out that seem to be
responsible for the appearance of LOAD, possibly through their
interaction with environmental factors and within a more complex
frame than mere Ab neurotoxicity.
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Although the importance of AD is playing an ever larger socio-
economic role worldwide, the pathological basis, as well as the po-
tential treatments of the disease, are still unclear. In the last dec-
ades, the amyloid hypothesis has achieved a relevant position.
However, the failure of clinical trials with anti-amyloid agents
and the recent ﬁndings in genetic and biological studies led to
reappraise the role of Ab and focalize interest on potential alterna-
tive explanations for the disease. In fact, several studies support
the hypothesis that SP formation is a reaction triggered as a de-
fense mechanism from a previous stress [164–166]. According to
these observations, proinﬂammatory molecules, including inter-
leukin 1 (IL-1b) [164,165,167,168] and TNFa converting enzyme
[169], can mediate the synthesis and release of APP. The response
to stress by plaque formation thus becomes toxic only in a later
phase of the process, possibly only when the disease becomes clin-
ically evident.
All the reported works support a theory in which typical alter-
ations of AD may occur independently from Ab deposition. In par-
ticular, we have seen that the alteration of synaptic plasticity can
occur early, and especially before the senile plaques formation. In
this context, presenilins seem to play a fundamental part, through
Ca2+ levels regulation and/or Notch pathway activation, both alter-
ing the pre-synaptic release of neurotransmitters. In recent years,
attention has been paid to the mTOR signaling, upregulated in
AD brains, that leads to glutammatergic transmission impairment
controlling tau amount in somatodendritic compartments. Equally
important are the functions of PS1 and fragments sAPPa, sAPPb
and AICD in cell cycle and in neuronal survival, while PS1 is also
involved in vesicular trafﬁcking mechanisms.
In conclusion, the wide clinical heterogeneity, which can range
from typical amnesic phenotype to frontal variant, logopenic apha-
sia or posterior atrophy, cannot be fully explained by the amyloid
hypothesis, but other factors concur to determine the phenotype of
the disease. In other words, we suggest that, rather than a single
pathology, Alzheimer’s dementia may be seen as a syndrome that
includes different clinical presentations which are underlined by
a series of possible etiological pathways.
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